Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BCAL Diagnostics Limited (BDX.AX)
Sydney, NSW, AU
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.96% | +2.63% | -6.02% | -35.00% | -23.53% | -25.71% | +4.00% | -16.13% | -68.80% | -68.80% | -68.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 |
|---|---|
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%-99.3% Q4'25: -97.7% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+22.7% Q4'25: -2.9% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-23,189.2% Q4'25: -6,917.6% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-33,254.7% Q4'25: -11,776.6% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-176.5% Q4'25: -524.0% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+46.0% Q4'25: +58.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.38× Q4'25: -0.20× (vs Q4'23)
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
718.7K
est: 900.0K (-20.1%)
|
2.79M
est: 1.00M (+179.1%)
|
3.10M
est: 3.10M (-0.1%)
|
21.6K
est: 2.50M (-99.1%)
|
12.40M
12.40M – 12.40M
+396.0% YoY
|
| EBITDA |
-4.06M
est: -900.0K (-351.7%)
|
-7.72M
est: -1.00M (-672.3%)
|
-5.67M
est: -3.10M (-82.8%)
|
-6.19M
est: -2.50M (-147.7%)
|
-12.40M
-12.40M – -12.40M
-396.0% YoY
|
| EBIT |
-4.09M
est: -900.0K (-353.9%)
|
-7.84M
est: -1.00M (-683.6%)
|
-6.03M
est: -3.10M (-94.4%)
|
-7.20M
est: -2.50M (-187.8%)
|
-12.40M
-12.40M – -12.40M
-396.0% YoY
|
| Net Income |
-3.39M
est: -7.55M (+55.2%)
|
-5.06M
est: -8.63M (+41.3%)
|
-6.40M
est: -5.75M (-11.2%)
|
-7.24M
est: -6.83M (-6.0%)
|
3.96M
3.96M – 3.96M
+157.9% YoY
|
| SGA |
1.83M
est: 46.46M (-96.1%)
|
3.31M
est: 51.62M (-93.6%)
|
4.18M
est: 160.03M (-97.4%)
|
5.39M
est: 129.05M (-95.8%)
|
640.11M
640.11M – 640.11M
+396.0% YoY
|
| EPS |
-0.02
est: -0.02 (+21.0%)
|
-0.02
est: -0.02 (+0.0%)
|
-0.03
est: -0.02 (-62.5%)
|
-0.02
est: -0.02 (-5.8%)
|
0.01
0.01 – 0.01
+157.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shane Ryan | Chief Executive Officer | 497.9K | male |
| Jayne Andrea Shaw | Co-Founder & Executive Chairman | 240.0K | female |
| Alexandra Feetham | Head of Innovation | — | — |
| Guy Adrian Robertson MAICD | Chief Financial Officer & Company Secretary | — | male |
| Sean Alexander Kennedy | Director of Corporate Finance | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BDX.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
